Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
- Conditions
- CarcinomaCancer of the SkinBasal Cell CarcinomaSkin CancerCancer of the Skin, Basal Cell
- Interventions
- Drug: LTX-315 Part 1Drug: VP-315 Part 2
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Verrica Pharmaceuticals Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT05188729
- Locations
- 🇺🇸
Therapeutics Clinical Research, San Diego, California, United States
🇺🇸Florida Center for Dermatology, Saint Augustine, Florida, United States
🇺🇸Gwinnett Dermatology, Snellville, Georgia, United States
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
- Conditions
- Papillomavirus InfectionsSexually Transmitted Diseases, ViralSkin Diseases, ViralWartsSexually Transmitted DiseasesCondylomata AcuminataSkin Diseases, InfectiousSkin Diseases
- Interventions
- Combination Product: VP-102 and applicatorCombination Product: Placebo
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Verrica Pharmaceuticals Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT03981822
- Locations
- 🇺🇸
Clarkston Skin Research, Clarkston, Michigan, United States
🇺🇸The Indiana Clinical Trials Center,PC, Plainfield, Indiana, United States
🇺🇸DelRicht Research, Tulsa, Oklahoma, United States
Cantharidin and Occlusion in Verruca Epithelium
- Conditions
- Skin Diseases, InfectiousSkin DiseasesVerrucaCommon WartDNA Virus InfectionsWarts HandVerruca VulgarisPapillomavirus InfectionsSkin Diseases, ViralVirus Diseases
- Interventions
- Combination Product: VP-102 Cantharidin topical film forming solutionCombination Product: VP-102 Cantharidin, topical film forming solution
- First Posted Date
- 2018-04-04
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Verrica Pharmaceuticals Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03487549
- Locations
- 🇺🇸
Cohort 2: Applied Research Center of Arkansas, Little Rock, Arkansas, United States
🇺🇸Cohort 2: The Indiana Clinical Trials Center, Plainfield, Indiana, United States
🇺🇸Cohort 1-Wake Research Associates, Raleigh, North Carolina, United States
Cantharidin Application in Molluscum Patients
- Conditions
- Molluscum Contagiosum
- Interventions
- Combination Product: VP-102 - Cantharidin, Topical Film Forming SolutionCombination Product: Placebo -Topical Film Forming Solution without VP-102
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Verrica Pharmaceuticals Inc.
- Target Recruit Count
- 262
- Registration Number
- NCT03377803
- Locations
- 🇺🇸
Pedia Research, Owensboro, Kentucky, United States
🇺🇸Midwest Children's Health, Lincoln, Nebraska, United States
🇺🇸Bakersfield Dermatology, Bakersfield, California, United States
Cantharidin Application in Molluscum Patients-1
- Conditions
- Molluscum Contagiosum
- Interventions
- Combination Product: VP-102 - Cantharidin, Topical Film Forming SolutionCombination Product: Placebo -Topical Film Forming Solution without VP-102
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Verrica Pharmaceuticals Inc.
- Target Recruit Count
- 266
- Registration Number
- NCT03377790
- Locations
- 🇺🇸
Study Protocol, Inc.,, Boynton Beach, Florida, United States
🇺🇸Summit Dermatology, Oakbrook Terrace, Illinois, United States
🇺🇸The Pediatric Associates of Fairfield, Inc, Fairfield, Ohio, United States
Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
- Conditions
- Molluscum Contagiosum
- Interventions
- Combination Product: VP-102 with applicator
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2021-08-11
- Lead Sponsor
- Verrica Pharmaceuticals Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT03186378
- Locations
- 🇺🇸
Midwest Children's Health, Lincoln, Nebraska, United States